PDE4D and metabolic dysfunction-associated steatotic liver disease: Taken together, our studies reinforce the notion that hepatic PDE4D mediates liver-kidney crosstalk in NAFLD-associated CKD via TGF-β1-SMAD signaling and thus provide a novel therapeutic strategy for CKD.